Dr. Colleen Walsh-Irwin joined NP Pulse to discuss updated treatment guidelines for hyperlipidemia and much more. Walsh-Irwin has been an NP for almost thirty years and runs a national program for evidence-based practice. In addition to discussing new medications for treating hyperlipidemia, Walsh-Irwin shares how she utilizes her own visual aides to help her patients understand their health issues and treatment.

And for all things Cardiovascular related, consider joining the AANP Community group: Cardiology Specialty Practice, which offers the opportunity to interactively collaborate with colleagues who share interest or clinical expertise on the subject.

On this episode, Margaret “Midge” Bowers returns to NP Pulse to discuss all things cardiovascular, with a focus on the newest atrial fibrillation and congestive heart failure guidelines. Bowers and Sophia Thomas also discuss new medications, the importance of communication between patient and provider — and why it is so necessary for NPs to “treat the person, not the number.”

If you are interested in learning more from Midge on this subject, listen to NP Pulse episode 106. Four Pillars of Medications for Heart Failure with Reduced Ejection Fraction and gain CE credit by going to the AANP CE Center here. CE credit is offered until February 2025.

Please also consider joining the AANP Community group: Cardiology Specialty Practice, which offers the opportunity to interactively collaborate with colleagues who share interest or clinical expertise on the subject.

Sickle cell disease (SCD) is a condition of immense and multifarious clinical gravity causing acute pain, joint damage, anemia and risk of infection, stroke, delayed growth in children and adolescents — as well as long-term organ dysfunction. However, recent evolutions in treatment options offer promising novel and emerging therapeutics poised to truly revolutionize SCD care. On this episode of NP Pulse: The Voice of the Nurse Practitioner®, nurse practitioner (NP) specialists Sheryl Mitchell and Artangela Henry guide NPs to achieve the following learning objectives:

• Describe the epidemiologic patterns, pathophysiologic principles and robust patient burden of SCD.
• Examine current best practices for SCD diagnosis, highlighting the fundamental importance of early disease detection, characterization and linkage to treatment.
• Evaluate the established and evolving therapeutic landscape for SCD, with a focus on recent regulatory approvals and emerging trial data for novel agents.
• Design individualized, evidence-driven treatment plans for patients with SCD that mitigate disease complications and improve quality of life.
• Identify residual unmet needs in the SCD treatment paradigm and discuss the role of ongoing research and comprehensive, multidisciplinary care strategies in closing these gaps.

This program and the accompanying clinical resource tool were made possible by a medical education grant from Vertex.

Continuing education (CE) credit for this program may be claimed through Dec. 31, 2025. To claim credit for this program, log in to the CE Center, search for this program by name and complete the post-test and evaluation by entering the participation code that is given after listening to the podcast.